UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
FORM 8-K
CURRENT REPORT
Pursuant
to Section 13 or 15(d)
of the Securities Exchange Act of 1934
Date of Report (Date of earliest event reported): February 10, 2016
Celladon Corporation
(Exact name of registrant as specified in its charter)
|
|
|
|
|
Delaware |
|
001-36183 |
|
33-0971591 |
(State or other jurisdiction
of incorporation) |
|
(Commission
File Number) |
|
(IRS Employer
Identification No.) |
|
|
|
|
|
12707 High Bluff Drive, Suite 200
San Diego, CA |
|
92130 |
(Address of principal executive offices) |
|
(Zip Code) |
Registrants telephone number, including area code: (858) 350-4355
Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligations of the registrant under any of the
following provisions:
|
x |
Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425) |
|
¨ |
Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12) |
|
¨ |
Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b)) |
|
¨ |
Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c)) |
Item 8.01 Other Events.
On February 10, 2016, Celladon Corporation (Celladon) issued a press release announcing that it has set a date for a special
meeting of its stockholders to vote on matters related to the previously announced proposed merger with Eiger BioPharmaceuticals, Inc. (Eiger). The special meeting will be held at 9:00 a.m., local time, on March 21, 2016 at 12255 El
Camino Real, Suite 300, San Diego, California 92130. Celladon stockholders of record as of the close of business on February 12, 2016 are entitled to receive notice of, and to vote at, the special meeting.
A copy of the press release is attached hereto as Exhibit 99.1 and incorporated by reference herein.
Additional Information about the Merger and Where to Find It
In connection with the proposed merger, Celladon has filed a registration statement on Form S-4 with the Securities and Exchange Commission
(the SEC), including a proxy statement/prospectus/information statement, but the registration statement has not yet become effective. The proxy statement/prospectus/information statement and any other relevant documents filed by Celladon
with the SEC may be obtained free of charge at the SEC web site at www.sec.gov. In addition, investors and security holders may obtain free copies of the documents filed with the SEC by Celladon by directing a written request to: Celladon
Corporation, 12707 High Bluff Dr. #200, San Diego, CA 92130, Attention: Investor Relations. Investors and security holders are urged to read the proxy statement/prospectus/information statement and the other relevant materials before making any
voting or investment decision with respect to the proposed merger.
This communication shall not constitute an offer to sell or the
solicitation of an offer to sell or the solicitation of an offer to buy any securities, nor shall there be any sale of securities in any jurisdiction in which such offer, solicitation or sale would be unlawful prior to registration or qualification
under the securities laws of any such jurisdiction. No offering of securities in connection with the proposed merger shall be made except by means of a prospectus meeting the requirements of Section 10 of the Securities Act of 1933, as amended.
Participants in the Solicitation
Celladon and its directors and executive officers and Eiger and its directors and executive officers may be deemed to be participants in the
solicitation of proxies from the stockholders of Celladon in connection with the proposed transaction. Information regarding the special interests of these directors and executive officers in the merger is included in the proxy
statement/prospectus/information statement referred to above. Additional information regarding the directors and executive officers of Celladon is also included in Celladons Annual Report on Form 10-K for the year ended December 31, 2014
and the proxy statement for Celladons 2015 Annual Meeting of Stockholders. These documents are available free of charge at the SEC web site at www.sec.gov and from Investor Relations at Celladon at the address described above.
2
Item 9.01 Financial Statements and Exhibits.
Reference is made to the Exhibit Index included with this Current Report on Form 8-K.
3
SIGNATURES
Pursuant to the requirements of the Securities Exchange Act of 1934, the Registrant has duly caused this report to be signed on its behalf by
the undersigned hereunto duly authorized.
|
|
|
|
|
|
|
|
|
|
|
Celladon Corporation |
|
|
|
Dated: February 10, 2016 |
|
|
|
|
|
|
|
|
|
|
|
|
By: |
|
/s/ Andrew C. Jackson |
|
|
|
|
|
|
Andrew C. Jackson |
|
|
|
|
|
|
Chief Financial Officer |
4
EXHIBIT INDEX
|
|
|
Exhibit No. |
|
Description |
|
|
99.1 |
|
Press release issued by Celladon Corporation on February 10, 2016 entitled Celladon Sets Date for Special Meeting of Stockholders. |
EXHIBIT 99.1
Celladon Sets Date for Special Meeting of Stockholders
San Diego, CA February 10, 2016 Celladon Corporation (Nasdaq: CLDN) announced today it has set a date for a special meeting of its
stockholders to vote on matters related to the proposed merger with Eiger BioPharmaceuticals, Inc.
The special meeting will be held at 9:00 a.m., local
time, on March 21, 2016 at 12255 El Camino Real, Suite 300, San Diego, California 92130. Celladon stockholders of record as of the close of business on February 12, 2016 are entitled to receive notice of, and to vote at, the special
meeting.
The merger has been unanimously approved by the boards of directors of both companies, and a majority of Eiger stockholders have agreed to vote
in favor of the transaction. The proposed merger is expected to close in the first half of 2016 (subject to the approval of the stockholders of each company as well as regulatory approval and other customary conditions).
Safe Harbor Statements
Additional Information
about the Proposed Merger between Celladon Corporation and Eiger BioPharmaceuticals, Inc. and Where to Find It
In connection with the proposed
merger, Celladon has filed a registration statement on Form S-4 with the Securities and Exchange Commission (the SEC), including a proxy statement/prospectus/information statement, but the registration statement has not yet become
effective. The proxy statement/prospectus/information statement and any other relevant documents filed by Celladon with the SEC may be obtained free of charge at the SEC web site at www.sec.gov. In addition, investors and security holders may obtain
free copies of the documents filed with the SEC by Celladon by directing a written request to: Celladon Corporation, 12707 High Bluff Dr. #200, San Diego, CA 92130, Attention: Investor Relations. Investors and security holders are urged to read
the proxy statement/prospectus/information statement and the other relevant materials before making any voting or investment decision with respect to the proposed merger.
This communication shall not constitute an offer to sell or the solicitation of an offer to sell or the solicitation of an offer to buy any securities, nor
shall there be any sale of securities in any jurisdiction in which such offer, solicitation or sale would be unlawful prior to registration or qualification under the securities laws of any such jurisdiction. No offering of securities in connection
with the proposed merger shall be made except by means of a prospectus meeting the requirements of Section 10 of the Securities Act of 1933, as amended.
Participants in the Solicitation
Celladon and its
directors and executive officers and Eiger and its directors and executive officers may be deemed to be participants in the solicitation of proxies from the stockholders of Celladon in connection with the proposed transaction. Information regarding
the special interests
of these directors and executive officers in the merger is included in the proxy statement/prospectus/information statement referred to above. Additional information regarding the directors and
executive officers of Celladon is also included in Celladon Annual Report on Form 10-K for the year ended December 31, 2014 and the proxy statement for Celladons 2015 Annual Meeting of Stockholders. These documents are available free of
charge at the SEC web site at www.sec.gov and from Investor Relations at Celladon at the address described above.
Forward-Looking Statements
Statements contained in this press release regarding matters that are not historical facts are forward-looking statements within the
meaning of the Private Securities Litigation Reform Act of 1995. Such statements include, but are not limited to, statements concerning the conduct of our special meeting of stockholders; statements regarding the structure, timing and completion of
our proposed merger with Eiger; and the expectations regarding voting by Celladon and Eiger stockholders. Celladon and/or Eiger may not actually achieve the proposed merger or otherwise carry out the intentions or meet the expectations or
projections disclosed in our forward-looking statements, and you should not place undue reliance on these forward-looking statements. Because such statements are subject to risks and uncertainties, actual results may differ materially from those
expressed or implied by such forward-looking statements. These forward-looking statements are based upon Celladons and Eigers current expectations and involve assumptions that may never materialize or may prove to be incorrect. Actual
results and the timing of events could differ materially from those anticipated in such forward-looking statements as a result of various risks and uncertainties, which include, without limitation, risks and uncertainties associated with stockholder
approval of and the ability to consummate the proposed merger through the process being conducted by Celladon and Eiger, the ability to project future cash utilization and reserves needed for contingent future liabilities and business operations,
the availability of sufficient resources for combined company operations and to conduct or continue planned clinical development programs, the ability to successfully develop any of Eigers product candidates, and the risks associated with the
process of developing, obtaining regulatory approval for and commercializing drug candidates that are safe and effective for use as human therapeutics. Risks and uncertainties facing Celladon are described more fully in Celladons periodic
reports and the Form S-4 registration statement filed with the SEC. All forward-looking statements contained in this press release speak only as of the date on which they were made. Celladon undertakes no obligation to update such statements to
reflect events that occur or circumstances that exist after the date on which they were made.
CONTACTS
Celladon Corporation
Fredrik Wiklund
Email: investors@celladon.com
CELLADON CORP (NASDAQ:CLDN)
Historical Stock Chart
From Jul 2024 to Aug 2024
CELLADON CORP (NASDAQ:CLDN)
Historical Stock Chart
From Aug 2023 to Aug 2024